QQ客服 官方微博 反馈留言

浏览/检索结果: 共17条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, 期刊论文 2019, 卷号: 42, 期号: 5, 页码: 432-439 作者:  Song, Yong;  Wu, Yi-Long;  Cao, Le-Jie;  Chen, Jian-Hua;  Ma, Zhi-Yong 收藏  |  浏览/下载：31/0  |  提交时间：2020/01/03 re-challenge  gefitinib  T790M mutation  progression-free survival  EGFR-TKI  NSCLC   Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease 期刊论文 2019, 卷号: 12, 页码: 5545-5549 作者:  Wang, Hanping;  Zhang, Li;  Shi, Xiaohua;  Zhang, Xiaotong;  Si, Xiaoyan 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 osimertinib  AC0010  interstitial lung disease  resistance mechanism  transformation  large-cell neuroendocrine carcinoma   Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy 期刊论文 2018, 卷号: 11, 页码: 7513-7519 作者:  Wang, Hanping;  Zhang, Li;  Si, Xiaoyan;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 re-biopsy  T790M mutation  resistant mechanism  EGFR-TKI  icotinib  non-small-cell lung cancer   Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation 期刊论文 2018, 卷号: 122, 页码: 1-6 作者:  Wang Hanping;  Zhang Li;  Hu Pei;  Zheng Xin;  Si Xiaoyan 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 Brain metastases  Cerebrospinal fluid  Penetration rate  T790M mutation  Third generation EGFR TKI   Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer 期刊论文 2018, 卷号: 92, 期号: 6, 页码: 1988-1997 作者:  Yi, Yuanyuan;  Wang, Luhong;  Zhao, Dan;  Huang, Shanshan;  Wang, Changyuan 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 EGFR T790M  inhibitors  NSCLC  pyrimidine  resistance   Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment 期刊论文 2018, 卷号: 423, 页码: 9-15 作者:  Li, Weihua;  Qiu, Tian;  Guo, Lei;  Ling, Yun;  Gao, Yibo 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/03 Non-small cell lung cancer  Primary EGFR T790M mutation  Acquired EGFR T790M mutation  Sensitizing EGFR mutation  Mutant allele frequency   Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS stud 会议论文 ANNALS OF ONCOLOGY, 2018-11-01 作者:  Zhou, Q.;  Zhang, H.;  Jiang, L.;  Shi, Y.;  Chen, Y. 收藏  |  浏览/下载：9/0  |  提交时间：2020/01/03 Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS stud 期刊论文 2018, 卷号: 29, 页码: 158-158 作者:  Zhou, Q.;  Zhang, H.;  Jiang, L.;  Shi, Y.;  Chen, Y. 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S1250-S1250 作者:  Zhou, Caicun;  Wang, Mengzhao;  Cheng, Ying;  Chen, Yuan;  Zhao, Yanqui 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 EGFR-TKI  T790M  osimertinib (AZD9291)  EGFR mutation   EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs 期刊论文 2017, 卷号: 403, 页码: 186-194 作者:  Liang, Zhiyong;  Cheng, Ying;  Chen, Yuan;  Hu, Yanping;  Liu, Wei-Ping 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 EGFR T790M mutation  Tyrosine kinase inhibitors  NSCLC  Drug resistance